Holen Sie sich die Stockscreener-App
1.85
1.07%
-0.02
Handel nachbörslich:
1.89
0.04
+2.16%
Schlusskurs vom Vortag:
$1.87
Offen:
$1.88
24-Stunden-Volumen:
16,195
Relative Volume:
0.12
Marktkapitalisierung:
$62.70M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-13.27M
KGV:
-11.28
EPS:
-0.164
Netto-Cashflow:
$-7.70M
1W Leistung:
+0.00%
1M Leistung:
+16.72%
6M Leistung:
+81.12%
1J Leistung:
+33.08%
1-Tages-Spanne:
$1.8001
$1.89
1-Wochen-Bereich:
$1.70
$1.9499
52-Wochen-Spanne:
$0.8075
$1.98
Okyo Pharma Limited Stock (OKYO) Company Profile
Firmenname
Okyo Pharma Limited
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie OKYO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
1.85 | 62.78M | 0 | -13.27M | -7.70M | -0.164 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Okyo Pharma Limited Aktie (OKYO) Neueste Nachrichten
OKYO Pharma (NASDAQ:OKYO) Stock Price Up 0.5% – Should You Buy? - Defense World
OKYO Pharma stock soars to 52-week high of $1.75 - Investing.com Australia
OKYO Pharma stock soars to 52-week high of $1.75 By Investing.com - Investing.com India
OKYO Pharma has dry eyes as a lucrative prize in its sights - Proactive Investors
OKYO Pharma CEO to Present at Boston Drug Discovery Summit - TipRanks
OKYO Pharma Limited CEO to Present on Urcosimod Development for Neuropathic Corneal Pain at GPCRs-Targeted Drug Discovery Summit - Nasdaq
OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit - GlobeNewswire
OKYO Pharma Advances First-Ever Treatment for Neuropathic Corneal Pain at Major Drug Summit - Stock Titan
OKYO Pharma ("OKYO" or the "Company")announces issuance of U.S. Patent No. 11,254,720 covering OKYO’s dry eye drug candidate OK-101 for use to treat ocular neuropathic pain - Barchart.com
OKYO Pharma’s (OKYO) Buy Rating Reaffirmed at HC Wainwright - Defense World
Neuropathic Ocular Pain Market Expected to Experience Major - openPR.com
Neuropathic Ocular Pain Market Expected to Experience Major Growth by 2034, According to DelveInsight | Novartis, OKYO Pharma, AbbVie Inc., Aciex Therapeutics, Novaliq, Oculeve and Allergan, Adverum - Barchart.com
Allergic Conjunctivitis Pipeline 2025: FDA Approvals, Therapies, Clinical Trials, and Latest Developments Unveiled by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO Pharma - Barchart.com
OKYO Pharma Limited (NASDAQ:OKYO) Sees Significant Decrease in Short Interest - Defense World
ADS Program collapse - Investegate
FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain - marketscreener.com
OKYO moves toward FDA talks after eye drug trial – ICYMI - Proactive financial news
FDA grants fast track to OKYO Pharma’s neuropathic pain drug - Investing.com Australia
Small cap wrap: GoviEx, NextSource Materials, Voyageur Pharmaceuticals, OKYO Pharma... - Proactive financial news
FDA grants fast track to OKYO Pharma’s neuropathic pain drug By Investing.com - Investing.com Nigeria
FDA grants fast track designation to OKYO Pharma’s urcosimod for treatment of neuropathic corneal pain - Ophthalmology Times
OKYO Pharma’s Urcosimod Receives FDA Fast Track Designation for Neuropathic Corneal Pain - TipRanks
FDA Fast-Tracks Novel Eye Pain Drug: OKYO's Urcosimod Targets Untreated Corneal Condition - Stock Titan
OKYO Pharma secures FDA fast-track designation for urcosimod for neuropathic corneal pain - Proactive financial news
OKYO Pharma accelerates neuropathic corneal pain treatment with early closure of Phase 2 trial - Proactive financial news
Market movers: Snap, Super Micro Computer, OKYO Pharma... - Proactive financial news
Okyo Pharma announces plans to accelerate development of urcosimod - TipRanks
OKYO Pharma Accelerates Urcosimod Development for Neuropathic Corneal Pain - TipRanks
OKYO Pharma speeds up NCP drug development - Investing.com
OKYO Pharma Announces Plans to Accelerate the Clinical - GlobeNewswire
OKYO Pharma Limited Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain - marketscreener.com
OKYO Pharma accelerates clinical development of urcosimod for neuropathic corneal pain - Proactive financial news
Press Release Distribution & PR Platform - ACCESS Newswire
OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain - ADVFN
OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain - ADVFN
Kyverna Therapeutics (NASDAQ:KYTX) and OKYO Pharma (NASDAQ:OKYO) Financial Review - Defense World
OKYO Pharma CEO discusses FDA Fast Track filing for urcosimodICYMI - Proactive financial news
OKYO Pharma achieves key stability milestone for Urcosimod in clinical development - Proactive financial news
OKYO Stock Price and Chart — NASDAQ:OKYO - TradingView
OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod - GlobeNewswire
Small cap wrap: OKYO Pharma, Charbone Hydrogen, Hillcrest... - Proactive financial news
OKYO Pharma reports long-term benefits of its neuropathic corneal pain treatment - Seeking Alpha
OKYO Pharma releases positive long-term stability data for urcosimod in neuropathic corneal pain - Ophthalmology Times
Urcosimod shows promise in long-term stability test - Investing.com
OKYO Pharma confirms stability of drug candidate By Investing.com - Investing.com South Africa
Urcosimod shows promise in long-term stability test By Investing.com - Investing.com India
OKYO Pharma Achieves Key Stability Milestone for Urcosimod - TipRanks
OKYO Pharma confirms stability of drug candidate - Investing.com
OKYO Pharma reports long-term shelf stability of corneal pain treatment - Proactive financial news
Dauntless Investment Group, LLC Acquires Significant Stake in OK - GuruFocus
Finanzdaten der Okyo Pharma Limited-Aktie (OKYO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):